"I'm proud to have been awarded the 2025 Hartwig Piepenbrock-DZNE Prize. Being able to give hope and contribute to the treatment of patients affected by Alzheimer's disease is what has driven me ...

In this uncontrolled environment, the pathological cascade of Alzheimer’s begins, with the formation of beta-amyloid protein ...

June is Brain and Alzheimer’s Awareness Month — a chance to examine real-world data that links new treatments to changing clinical behavior.

The EU has approved Eisai and Biogen's Leqembi for a subset of patients with early-stage Alzheimer's disease, more than two years after it was filed.

New Data: Wide Disparities in Access to Lecanemab Early use of lecanemab by Medicare beneficiaries with Alzheimer’s or mild cognitive impairment is marked by racial, ethnic, and socioeconomic ...